CssBA

BIOLOGICAL2 trials

Sponsors

PATH, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

DiarrheaEscherichia Infection

Phase 1

Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)

CompletedNCT03404674

Start: 2018-01-16End: 2019-03-26Updated: 2021-01-06

Phase 2

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

Active, not recruitingNCT06692907

National Institute of Allergy and Infectious Diseases (NIAID)Escherichia Infection

Start: 2025-03-31End: 2026-08-20Updated: 2026-03-16

Related Papers

Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermally.

2025-02-011 citations